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Running	head:	CARDIOVASCULAR	TOXICITY	IN	MM	
	
Abstract	
The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one 
of the standard therapies in relapsed and/or refractory multiple myeloma (MM) patients and 
produces impressive response rates in newly diagnosed MM as well. However, carfilzomib-related 
cardiovascular adverse events (CVAEs) – including hypertension (all grades: 12.2%; grade ≥3: 4.3%), 
heart failure (all grades: 4.1%; grade ≥3: 2.5%) and ischemic heart disease (all grades: 1.8%; grade 
≥3: 0.8%) – may lead to treatment suspensions. At present, there are neither prospective studies nor 
expert consensus on the prevention, monitoring and treatment of CVAEs in myeloma patients treated 
with carfilzomib. 
An expert panel of the European Myeloma Network in collaboration with the Italian Society of 
Arterial Hypertension and with the endorsement of the European Hematology Association aimed to 
provide recommendations to support health professionals in selecting the best management 
strategies for patients, considering the impact on outcome, the risk-benefit ratio of diagnostic and 
therapeutic tools and thereby to achieve myeloma response with novel combination approaches, 
while preventing CVAEs. 
Patients scheduled to receive carfilzomib need a careful cardiovascular evaluation before treatment 
and an accurate follow-up during treatment. A detailed clinical assessment before starting 
carfilzomib treatment is essential to identify patients at risk for CVAEs, and accurate monitoring of 
blood pressure and of early signs and symptoms suggestive of cardiac dysfunction remains pivotal to 
safely administer carfilzomib without treatment interruptions or dose reductions. 
 
Keywords: multiple myeloma, cardiovascular toxicity, carfilzomib, adverse events, clinical 
assessment, blood pressure monitoring 
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INTRODUCTION 
Carfilzomib (CFZ), a second-generation proteasome inhibitor (PI), is active as a single agent and in 
combination with other anti-multiple myeloma (MM) agents. CFZ  has been approved in Europe for 
the treatment of relapsed/refractory MM (RRMM), in combination with lenalidomide and/or 
dexamethasone, based on the randomized trials ASPIRE [1] and ENDEAVOR [2]. In ASPIRE, 792 
patients were randomized to receive CFZ with lenalidomide and dexamethasone (KRd) or 
lenalidomide and dexamethasone alone (Rd). In ENDEAVOR, 929 patients were randomized to 
receive CFZ with dexamethasone (Kd) or bortezomib with dexamethasone (Vd). CFZ-based regimens, 
KRd and Kd, are the first therapy combinations to demonstrate a significant overall survival (OS) 
advantage (21% reduction of risk of death, resulting in nearly eight additional months of OS) for 
relapsed MM patients versus recent standards-of-care (Rd and Vd) [3]. 
However, in ASPIRE and ENDEAVOR, KRd and Kd treatments were associated with higher than 
expected rates of hypertension (all grades: 14.3% and 16%; grade ≥3: 4.3% and 9%), heart failure 
(HF) (all grades: 6.4% and 3%; grade ≥3: 3.8% and 4.8%) and ischemic heart disease (all grades: 
5.9% and 0.9%; grade ≥3: 3.3% and 1.7%, respectively) [1,2]. 
A recent meta-analysis performed on 24 clinical studies with available non-hematological adverse 
events data associated with CFZ treatment showed that the incidence of all-grade and grades ≥3 
cardiovascular adverse events (CVAEs) was 18.1% and 8.2%, respectively. In randomized clinical 
trials, the relative risk (CFZ vs controls) of all-grade and grade ≥3 CVAEs were 1.8 and 2.2, respectively 
[4]. The most frequent CVAEs during treatment with CFZ are hypertension (all grades: 12.2%; grade 
≥3: 4.3%), heart failure (all grades: 4.1%; grade ≥3: 2.5%) and ischemic heart disease (all grades: 
1.8%; grades ≥3: 0.8%). Dyspnea is another particular issue, which is reported in patients treated 
with CFZ with an incidence of 23.9% (all grades) and 3.2% (grades ≥3). Although the causes are not 
clear, it could be a symptom related to cardiovascular conditions, such as cardiac failure, as well as 
pulmonary complications. Venous thromboembolic events and thrombotic microangiopathy have 
also been reported in patients who received CFZ [1–11]. 
The mechanisms by which CFZ induces CVAEs are poorly understood. However, speculations can be 
made on its irreversible and highly potent proteasome inhibition activity that could differentiate its 
safety profile from that of bortezomib [12]. Cardiac stress produces misfolded proteins; proteasome-
mediated degradation of these toxic products is pivotal to preserve cellular function in some patients 
[13,14]. Moreover, the levels of nitric oxide, an important mediator of endothelial function, could also 
be modulated by proteasome activity, and decreased nitric oxide levels could impair vasodilatation, 
inducing hypertension and cardiac dysfunction [15]. 
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Neither prospective studies nor expert consensus have been reported so far on the prevention, 
monitoring and treatment of CVAEs in MM patients treated with CFZ. Therefore, this European 
Myeloma Network (EMN) consensus paper, in collaboration with the Italian Society of Arterial 
Hypertension (SIIA) and the support of the European Hematology Association (EHA), aims to help 
physicians to prevent and manage CVAEs during CFZ treatment, thereby improving the risk/benefit 
ratio of this widely used drug. 
The currently available guidelines on cancer treatments and cardiotoxicity are based on studies 
performed on tumor entities other than MM and are discussed in the Supplementary	Appendix. 
 
RISK	FACTORS 
To identify patients at increased risk for CVAEs, the first step is a careful baseline assessment of 
cardiovascular risk factors and prior cardiovascular diseases (Table	1,	Figure	1) as well as prior 
exposition to cardiotoxic treatments (e.g. anthracyclines or chest radiotherapy) (Table	S2) [5]. No 
data are available on prior exposition to proteasome inhibitors as a risk factor. 
The most frequent CVAE is hypertension, which is itself a trigger event for other CVAEs, such as heart 
failure and ischemic heart disease. According to the ESH/ESC guidelines for the management of 
arterial hypertension [16], the estimation of all cardiovascular risks should be performed with a 
detailed stratification (Table	1,	Figure	1) or with the handier Systematic Coronary Risk Evaluation 
(SCORE) model that estimates the risk of dying from cardiovascular disease over 10 years [17]. 
Arterial hypertension is defined by a systolic blood pressure ≥140 mmHg and/or a diastolic blood 
pressure ≥90mmHg.  Methods used to monitor patients' blood pressure are: 
1. Office blood pressure monitoring: this is usually higher than out of office blood pressure and 
home blood pressure and the difference increases as office blood pressure increases. 
2. Out-of-office blood pressure monitoring: it provides many blood pressure measurements 
away from the medical environment, which correlates better with actual blood pressure than 
office blood pressure. Out-of-office blood pressure is commonly assessed by ambulatory blood 
pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) (Table	2). 
 
For initial assessment, HBPM may be better suitable in primary care and ABPM in specialist care. 
However, borderline or abnormal findings on HBPM should be confirmed with ABPM [18], which is 
currently considered the reference for out-of-office blood pressure. Furthermore, defining values for 
arterial hypertension according to HBPM (systolic blood pressure >135 mmHg and/or a diastolic 
blood pressure >85 mmHg) are slightly lower than the classical definition of arterial hypertension 
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[16]. Patients should be routinely trained for self-measurement of blood pressure to optimize follow-
up, for which HBPM is more suitable than ABPM.  
Hypertension Mediated Organ Damage (HMOD) (Figure	 S1) predicts cardiovascular death 
independently of ESH/ESC guidelines and/or SCORE model (http://www.heartscore.org), so it 
should be accurately screened. 
 
ROLE	OF	BIOMARKERS	
Cardiac biomarkers are not essential parameters in clinical practice for the early detection of 
cardiotoxicity, even though they have a role in patients who develop cardiotoxicity. Available data on 
cardiac biomarkers are described in the Supplementary	Appendix. 
	
ROLE	OF	IMAGING 
Evaluation of cardiac organ damage represents a pivotal step in cardiovascular risk stratification of 
the general population [19]. A similar approach to risk stratification could be applied to MM patients 
candidates for CFZ therapy. A comprehensive assessment requires evaluation of both structural and 
functional features, with different diagnostic tools. 
Standard	 echocardiography. The most frequently used parameter for routine cardiotoxicity 
monitoring is LVEF. A LVEF of >52% for men and >54% for women is considered normal [20,21]. A 
LVEF drop of >10% or >5% with heart failure symptoms is considered diagnostic of cardiotoxicity. 
LVEF before chemotherapy is considered as a predictor of subsequent cardiotoxicity. Nevertheless, 
the prognostic value and the timing of serial measurements of LVEF during treatment for 
cardiotoxicity detection and monitoring are still controversial. A sub-analysis of the ENDEAVOR study 
on 151 patients randomized between Kd vs Vd failed to demonstrate a lower LVEF in Kd-treated 
patients and serial screening with echocardiography in unselected patients was not helpful to 
mitigate the risk of CVAEs [7]. However, echocardiography assessment can be helpful to obtain a 
baseline evaluation of LVEF in patients before treatment and in case of established CVAEs for 
diagnostic purposes. 
Advanced	echocardiographic	evaluation. Myocardial deformations can be studied using different 
ultrasound techniques as Tissue Doppler and 2D and 3D speckle-tracking echocardiography [22]. 
Tissue Doppler is more sensitive than LVEF assessments in recognizing chemo- and/or radiotherapy-
induced left ventricle systolic dysfunction, early cardiotoxicity even for low-dose chemotherapy, and 
differences in regional myocardial function secondary to localized drug damage (i.e., the 
interventricular septum) [23]. However, Tissue Doppler has several limitations, such as a low 
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reproducibility with angle dependency, a limited spatial resolution, a high sensitivity to signal noise 
and a high inter-observer variability. 
Global Longitudinal Strain (GLS) assessed using automated speckle-tracking echocardiography is an 
emerging technique for detecting and quantifying subtle disturbances in LV systolic function. GLS 
reflects the longitudinal contraction of the myocardium and its accuracy has been validated against 
tagged magnetic resonance imaging [24]. GLS provides more consistent results than radial and 
circumferential myocardial deformation analyses in the early recognition of myocardial damage, the 
prediction of late cardiotoxicity onset, and the planning of cardio-protection strategies. There is 
evidence that GLS is the most sensitive and specific measurement for the early detection of subclinical 
myocardial injury [25]. The American Society of Echocardiography (ASE) and European Association 
of Cardiovascular Imaging (EACVI) consensus [26] suggested a practical approach for GLS use in 
patients undergoing chemotherapy. More precisely, a GLS reduction <8% from baseline is not 
meaningful, but >15% from baseline is very likely abnormal. 
In our experience, 28 consecutive relapsed/refractory MM (RRMM) patients treated with bortezomib 
(BTZ) and CFZ were compared with a population of 22 non-MM control subjects, matched for age, sex 
and mean 24h blood pressure [27]. All patients underwent trans-thoracic echocardiography, ABPM 
and a pulse-wave velocity study, to assess cardiac morphology and function, blood pressure load and 
arterial stiffness. Pulse wave velocity was similar between PI-treated patients and controls. GLS was 
the only echocardiographic parameter significantly decreased in PI-treated (p=0.02) and in CFZ-
treated patients (p=0.002), even after correction for the main cardiac function parameters (p=0.01 
and p=0.036, respectively). Among CFZ patients, we also found increased values of LV mass indexed 
by Body Surface Area (p=0.047). Moreover, in this cohort, the cumulative dose of CFZ was associated 
with a more prominent modification of GLS and LV mass indexed by Body Surface Area [27]. 
Cardiac	magnetic	resonance. Cardiac magnetic resonance is the reference standard in assessing LV 
and right ventricle volumes and function, and it is now extensively used to detect acute and chronic 
cardiac chemotherapy complications [28]. Cardiac magnetic resonance is superior to 
echocardiography for many reasons, but it has several limitations (low availability, high costs, 
contraindication to ferromagnetic devices). 
Radionuclide	angiography	(multigated	angiography-MUGA). Multigated angiography has been 
the ‘gold standard’ imaging technique to evaluate LV systolic function in patients undergoing 
chemotherapy for many years [29]. The main limit of MUGA is radiation exposure, which reduces its 
use after increasing availability of other imaging techniques. Multigated angiography also does not 
provide comprehensive information on right ventricle function, left and right atrial size, and presence 
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or absence of valvular or pericardial disease. The ASE and EACVI positions on the role of imaging 
techniques in cardiotoxicity management are summarized in Table	3 [26]. 
 
PREVENTION	OF	CHEMOTHERAPY-INDUCED	CARDIOTOXICITY	IN	CANCER	PATIENTS 
β-blockers. It is well known that chronic activation of the sympathetic nervous system plays an 
important role in heart failure pathogenesis; therefore, ß-blockers should be used in all patients with 
reduced LVEF to prevent heart failure-related hospitalization and mortality. However, the use of ß-
blockers in oncologic patients undergoing chemotherapy, with asymptomatic LV dysfunction, is as yet 
not well established [30]. 
Renin-angiotensin-aldosterone	 system:	 angiotensin-converting-enzyme	 inhibitors	 (ACE-i)	
and	 angiotensin	 II	 receptor	 blockers	 (ARB). The activation of renin-angiotensin-aldosterone 
system is one of the potential mechanisms involved in chemotherapy-induced cardiotoxicity. 
Angiotensin-converting-enzyme inhibitors attenuate oxidative stress, reduce interstitial fibrosis, and 
improve intracellular calcium handling, cardiomyocyte metabolism and mitochondrial function, and 
there is good evidence on their efficacy in anthracycline-induced cardiotoxicity [30,31]. The efficacy 
of a combined therapy with ACE-i and ß-blockers in preventing cardiotoxicity has been demonstrated 
in the OVERCOME trial [32]. This study evaluated the efficacy of enalapril and carvedilol in preventing 
chemotherapy-induced LV systolic dysfunction in patients with hematologic diseases treated with 
conventional chemotherapy. Results showed a lower reduction in LV function and a lower incidence 
of heart failure in patients treated with this combination treatment compared to placebo. As a 
consequence, ACE-i and ß-blockers proved beneficial in conventional-chemotherapy induced 
cardiotoxicity. The PRADA trial demonstrated that in patients treated for early breast cancer with 
anthracycline-containing regimens with or without trastuzumab and radiation, the treatment with 
the ARB candesartan provided protection against early decline in global left ventricular function, 
while no short-term beneficial effect was observed for the β-blocker metoprolol alone [33]. 
Nutritional	 supplementation	 and	 exercise	 training. Non-pharmacologic strategies to reduce 
chemotherapy-induced cardiotoxicity are discussed in the Supplementary	Appendix.  
 
SUGGESTIONS	FOR	WORK-UP	IN	MM	PATIENTS	CANDIDATE	TO	CFZ	THERAPY 
In general, no differences in CVAEs were observed between RRMM and newly diagnosed MM patients, 
nor among different treatment combinations [4]. According to these data, an appropriate 
cardiovascular risk assessment is recommended for all patients receiving CFZ (Figure	1	and	2):  
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• Patients with no cardiovascular risks and normal blood pressure can start treatment with CFZ 
immediately.  
• Patients with low-moderate risk should correct modifiable risk factors and hypertension.  
• High-risk patients should undergo a case by case evaluation considering the risk/benefit. 
• Very high-risk patients are more likely to have not modifiable risk factors, treatment options 
other than CFZ should be considered.   
A slightly higher incidence of CVAEs was reported in patients receiving higher doses of CFZ 
(≥45mg/m2) [4] and in elderly patients (≥75 years): thus, these subgroups should be strictly 
monitored. No suggestions could be done for the use of CFZ in amyloidosis patients outside of clinical 
trials because it is not approved by FDA or EMA and few data are available. 
 
Before starting therapy 
Clinicians should perform a comprehensive work-up: 
• Medical history: to determine previous cardiovascular events and risk factors (hypertension, 
diabetes, dyslipidemia, obesity, smoking, etc.) as well as prior exposition to cardiotoxic cancer 
treatments (Table S2); 
• Physical examination: 
 Blood pressure (hypertension is a potent and modifiable risk factor for cardiac dysfunction 
onset, and should be assessed before starting treatment); 
 Heart auscultation to identify murmurs (significant valvular heart disease is a risk factor 
for cardiac dysfunction); 
 Signs of heart failure (elevated venous pressure, lung crackles or pedal edema); 
• 12-lead electrocardiogram (ECG) to detect possible markers of structural heart disease, 
including LV damage/dysfunction, arrhythmias (atrial fibrillation, atrial flutter, heart block), 
evidence of previous myocardial infarction (Q-waves, left bundle branch block), and evidence 
of LV hypertrophy; 
• LVEF measurement using echocardiography, cardiac magnetic resonance or MUGA to assess 
asymptomatic cardiac organ damage and to have a baseline evaluation useful as a reference in 
case of CVAEs; 
• ABPM/HBPM (Table 2) to detect unknown, borderline or uncontrolled hypertension. 
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Patients with home blood pressure >135/85mmHg should be treated; those already receiving 
hypertensive medication may need adjustments in their medication to manage their blood 
pressure before the start of CFZ treatment. 
 
During	therapy 
• Clinicians should manage modifiable cardiovascular risk factors (smoking, hypertension, 
diabetes, dyslipidemia, obesity) in all patients. 
• An aggressive hydration should be avoided and patients should be monitored for signs and 
symptoms of fluid overload, including weight gain. In the majority of patients, 250 mL hydration 
before CFZ infusion in cycle 1 is sufficient to prevent or reduce any acute renal function 
impairment. Any additional hydration is based on physician discretion according to the risk of 
lysis syndrome. 
• In case of severe dyspnea, CFZ should be temporarily discontinued until symptoms disappear or 
return to baseline levels. Dyspnea may be caused by fluid overload rather than drug toxicity. If 
aggressive hydration is not expected to be tolerated by the patient, serum creatinine may be 
monitored and, if stable, hydration may be decreased or discontinued. Most patients with dyspnea 
as primary manifestation of a potential cardiac disease do not typically show an EF impairment 
or other evidence of myocardial dysfunction. In these patients, CFZ could be restarted as soon as 
symptoms improve. 
• Home blood pressure monitoring is recommended during treatment: if home blood pressure 
values exceed >135/85 mmHg in at least 2 measurements, CFZ should be temporarily held and 
hypertensive therapy should be adjusted until blood pressure target levels are reached (≤135/85 
mmHg) (Figure	2,	Table	S3).  No clear recommendation for an antihypertensive agent can be 
made in this context, due to the lack of controlled studies. The most commonly prescribed 
antihypertensive agents are ACE-I and ARBs, dihydropyridine calcium channel blockers, ß-
blockers and diuretics [34]. 
• In patients with clinical signs or symptoms suggestive for grade ≥2 cardiac dysfunction, CFZ 
should be temporarily discontinued until recovery and the following strategy is recommended: 
– ECG and echocardiogram with echocardiography-derived strain for diagnostic workup; 
– Cardiac magnetic resonance (preferred) or MUGA if echocardiogram is not available or 
technically feasible (e.g., poor image quality). 
– Serum cardiac biomarkers (cardiac troponin, brain natriuretic peptides). 
– Cardiologist’s referral depending on findings. 
 12 
 
No recommendations can be made regarding further continuation or discontinuation of MM-therapy 
in patients with evidence of cardiac dysfunction during treatment, as long as cardiac function has 
recovered to grade 1 or baseline. This decision should be taken by the hematologist in close 
collaboration with the cardiologist, evaluating both the clinical circumstances and the risks/benefits 
of continuation of therapy responsible for the cardiac dysfunction.  
CFZ relationship with the emerging CVAE should be assessed. If grade 3/4 CVAEs are related to CFZ 
use, dose reductions or definitive discontinuation may be needed.  
CFZ treatment could be restarted at the dose used before the event, or at a reduced dose if the CVAE 
was not related to CFZ. 
Specific thromboprophylaxis strategies are recommended in MM patients regardless of CFZ 
treatment and have been discussed elsewhere [35]. 
 
CONCLUSIONS 
With the use of cardiotoxic drugs, hematologists need to develop strategies to identify and manage 
cardiovascular risk in clinical investigations and in general practice. The highly effective agent CFZ is 
associated with CVAE risks. Since this agent has shown to improve both PFS and OS compared to 
standard treatment in RRMM patients, avoiding toxicities that may prevent patient access to CFZ has 
become a priority. However, the risk-benefit ratio for an agent should be interpreted depending on 
the nature and severity of the disease, and restrictive approaches can potentially delay or prevent the 
access to innovative treatments. This consensus paper considers the best available present evidence 
and the application of data from large trials and provides clinically useful recommendation and 
treatment algorithms for its safe use (Figures 1-2). Future studies should prospectively analyze the 
mechanism of cardiovascular damage, the risk factors of developing CVAEs (including new 
techniques such as global longitudinal strain) and the potential role of cardio-protective drugs. 
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5. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et	al. 2016 ESC Position Paper on cancer treatments and 
cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The 
Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur	
Heart	J 2016; 37: 2768–801. 
6. Siegel D, Martin T, Nooka A, et	al. Integrated safety profile of single-agent carfilzomib: experience from 526 
patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753–61. 
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Table	1.	Factors influencing the stratification of total cardiovascular risk [36] 
 
Demographic characteristics and laboratory parameters 
Sexa (men >women) 
Agea 
Smoking (current or past history)a 
Total cholesterola and HDL-C 
Uric acid 
Diabetesa 
Overweight or obesity 
Family history of premature CVD (men aged <55 years and women aged <65 years) 
Family or parental history of early-onset hypertension 
Early-onset menopause 
Sedentary lifestyle 
Psychosocial and socioeconomic factors 
Heart rate (resting values >80 beats/min) 
Asymptomatic HMOD 
Arterial stiffening: 
Pulse pressure (in older people) ≥60 mmHg 
Carotid–femoral PWV >10 m/s 
ECG LVH (Sokolow–Lyon index >35 mm, or R in aVL ≥11 mm; Cornell voltage duration product 
>2440 mm.ms, or Cornell voltage >28 mm in men or >20 mm in women) 
Echocardiographic LVH [LV mass index: men >50 g/m2.7; women >47 g/m2.7 (height in m2.7); index-
ation for BSA may be used in normal-weight patients; LV mass/BSA g/m2 >115 (men) and >95 
(women)] 
Microalbuminuria (30–300 mg/24 h), or elevated albumin–creatinine ratio (30–300 mg/g; 3.4–34 
mg/mmol) (preferentially on morning spot urine)b 
Moderate CKD with eGFR >30–59 mL/min/1.73 m2 (BSA) or severe CKD eGFR <30 mL/min/1.73 
m2 b 
Ankle-brachial index <0.9 
Advanced retinopathy: haemorrhages or exudates, papilloedema 
Established CV or renal disease 
Cerebrovascular disease: ischaemic stroke, cerebral haemorrhage, TIA 
CAD: myocardial infarction, angina, myocardial revascularization 
Presence of atheromatous plaque on imaging 
Heart failure, including HFpEF 
Peripheral artery disease 
Atrial fibrillation 
BSA = body surface area; CAD = coronary artery disease; CKD = chronic kidney disease; CV = cardiovascular; CVD = 
cardiovascular disease; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HDL-C = HDL cholesterol; 
HFpEF = heart failure with preserved ejection fraction; HMOD = hypertension-mediated organ damage; LV = left 
ventricular; LVH = left ventricular hypertrophy; PWV = pulse wave velocity; SCORE = Systematic COronary Risk 
Evaluation; TIA = transient ischaemic attack.  
aCV risk factors included in the SCORE system. 
bProteinuria and reduced eGFR are independent risk factors. 
 
Source: Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial 
hypertension. Eur Heart J 2018; 39: 3021–104; Table 4, p. 3031. Publisher: Oxford University Press. DOI: 
10.1093/eurheartj/ehy339. 
https://academic.oup.com/eurheartj/article/39/33/3021/5079119 (Last accessed: Sept 21, 2018). 
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Table	 2. Main features of ambulatory blood pressure monitoring and home blood 
pressure monitoring 
 
 ABPM HBPM 
Brief description Blood pressure measurement 
with a portable blood pressure 
measuring device for a 24 hours 
period. 
Blood pressure self-
measurements daily for at least 
3–4 days and preferably for 7 
consecutive days. 
Primary care - + 
Specialist care + - 
Cheap - ++ 
24 hour ++ - 
Daily activity ++ - 
Sleep ++ - 
Long period (at least 7 days) - ++ 
ABPM= ambulatory blood pressure monitoring; HBPM= home blood pressure monitoring 
 
 
 
Table 3. The role of imaging in the management of CVAEs 
 
Echocardiography is the first-choice method for evaluating patients before, during and 
after chemotherapy, and Left Ventricular Ejection Fraction (LVEF) is the primary 
technique. 
Cardiotoxicity cannot be predicted by LVEF alone but an accurate echocardiographic 
investigation is strongly recommended, if available, to integrate the standard 
examination with data from different imaging techniques (Tissue Doppler Imaging 
and speckle-tracking echocardiography). 
Diastolic indices are not useful for early detection of cardiotoxicity because of their 
inability to predict heart failure. 
Global Longitudinal Strain (GLS) should be performed only by speckle-tracking 
echocardiography for a sensitive diagnosis of chemotherapy-induced cardiac damage, 
and the same ultrasound equipment should be used for serial examinations. 
Cardiac magnetic resonance is recommended for LVEF quantification when the 
quality of echocardiogram is suboptimal. Furthermore, cardiac magnetic resonance is 
suggested for confirming a LVEF <53%. 
Multigated angiography provides a highly reproducible quantification of LVEF during 
cancer therapy, but radiation exposure remains its main limitation. Therefore, this 
technique should be considered only when first line echocardiography and second line 
cardiac magnetic resonance are unavailable. 
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Main figures 
 
Figure 1. Classification of hypertension stages according to blood pressure levels, presence of 
cardiovascular risk factors, hypertension-mediated organ damage, or comorbidities, defined by 
the 2018 ESC/ESH Guidelines 
 
 
 
Legend: 
CV risk is illustrated for a middle-aged male. The CV risk does not necessarily correspond to the actual risk at 
different ages. The use of the SCORE system is recommended for formal estimation of CV risk for treatment 
decisions. BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; DBP = diastolic blood pressure; 
HMOD = hypertension-mediated organ damage; SBP = systolic blood pressure; SCORE = Systematic COronary Risk 
Evaluation.  
Source: Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial 
hypertension. Eur Heart J 2018; 39: 3021–104; Figure 1, p. 3034. Publisher: Oxford University Press. DOI: 
10.1093/eurheartj/ehy339. 
https://academic.oup.com/eurheartj/article/39/33/3021/5079119 (Last accessed: Sept 21, 2018). 
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Figure	2.	Flowchart for patient selection and evaluation before and during treatment with CFZ 
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Legend: 
CV = cardiovascular; ECG = electrocardiogram; ABPM = ambulatory blood pressure monitoring; HBPM = home 
blood pressure monitoring; BP = blood pressure; CFZ = carfilzomib; CMR = cardiac magnetic resonance; MUGA = 
multigated angiography; RAAS = Renin-angiotensin-aldosterone system; ACE-I = angiotensin-converting-enzyme 
inhibitors; ARB = angiotensin II receptor blockers. 
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